Contrast MRI Findings for Spinal Schwannoma As Predictors of Tumor Proliferation and Motor Status
Overview
Authors
Affiliations
Study Design: Retrospective analysis.
Objective: The goal of this study was to examine the relationship of the proliferation potency based on the MIB-1 index and motor status with features of T2-weighted images (T2WI) and contrast T1-weighted images (T1WI) of spinal schwannoma.
Summary Of Background Data: Spinal schwannomas account for 55% of spinal tumors, but the relationship of cellular proliferation with MRI findings for spinal schwannoma is unknown.
Methods: The subjects were 48 patients (22 males and 26 females) with spinal schwannoma who were classified into three subgroups: iso/homo, high/rim, and hetero/hetero, based on T2WI/contrast T1WI. A retrospective analysis of tumor size and MIB-1 index was performed in the context of these MRI findings. Intraoperative findings and pre- and postoperative motor performance were also examined.
Results: The average tumor size was 32.4 mm (range 10-130 mm) and the average MIB-1 index was 3.8% (range 1-12). In the three subgroups, there were no significant differences in sex, age, duration of disease, tumor lesion, and dumbbell type. In the hetero/hetero group, the tumor size was significantly greater and the MIB-1 index was significantly higher (both P < 0.05), than the other two groups. The tumor adherence rate was significantly higher for hetero tumors (P < 0.05) and preoperative paralysis was more common in cases with tumor adhesion. The rate of paralysis improvement at 1 month was significantly lower for hetero tumors, but all cases had improved at 6 months.
Conclusion: Contrast T1WI MRI was useful for prediction of the proliferative activity and growth of spinal schwannomas, which are associated with increased tumor size and adhesion. A heterogeneous pattern on contrast T1WI indicated an increase in size and adhesion of the tumor. This pattern reflected the preoperative motor status and postoperative motor recovery.
Level Of Evidence: 4.
Abudueryimu A, Shoukeer K, Ma H Front Neurol. 2024; 15:1408716.
PMID: 39318871 PMC: 11421035. DOI: 10.3389/fneur.2024.1408716.
Sodium Fluorescein for Spinal Intradural Tumors.
Olguner S, Arslan A, Acik V, Istemen I, Can M, Gezercan Y Front Oncol. 2021; 10:618579.
PMID: 33585245 PMC: 7877540. DOI: 10.3389/fonc.2020.618579.
Imaging features of primary spinal osseous tumors and their value in clinical diagnosis.
Yang L, Zhang S, Gu R, Peng C, Wu M Oncol Lett. 2019; 17(1):1089-1093.
PMID: 30655869 PMC: 6312963. DOI: 10.3892/ol.2018.9659.